If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. Decades of pharmacovigilance research have identified key factors—such as JC virus antibody status, prior immunosuppressant use, and treatment duration—that influence individual risk. This page summarizes the published evidence to help you recognize who may need closer monitoring and what the science says about risk stratification.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease when other treatments are not appropriate. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes medical evidence and risk considerations relevant to patients and their legal representatives. Clinical Presentation and Diagnosis of PML PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition results from reactivation of the JC virus, which damages oligodendrocytes and causes progressive demyelination. Early symptoms may include cognitive changes, motor weakness, visual disturbances, or speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Prompt recognition is critical because the disease can progress rapidly. Tysabri Pharmacology and Reported Adverse Effects Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. While this mechanism reduces MS relapses, it also impairs immune surveillance against JC virus. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 MS patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and viral infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The primary mechanism is reduced immune surveillance within the central nervous system. By blocking lymphocyte trafficking, Tysabri limits the ability of the immune system to control JC virus replication. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adequacy of Warnings The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies the three risk factors and instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML. Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and prescribers fully understood the magnitude of risk, particularly regarding the interaction of multiple risk factors and the importance of early symptom recognition.
Patients who develop PML after Tysabri treatment may face catastrophic outcomes, including permanent disability or death. Legal considerations often focus on whether the manufacturer provided adequate warnings about PML risk and whether healthcare providers appropriately monitored patients. Key factors in potential litigation include: documentation of anti-JCV antibody testing before and during treatment, duration of Tysabri use, prior immunosuppressant exposure, and the timeline between symptom onset and diagnosis. Patients should preserve all medical records, including infusion logs, MRI reports, and laboratory results. The restricted distribution program (TOUCH) may also be scrutinized regarding whether it effectively ensured informed consent and risk mitigation. Timeline Between Exposure and Documented Harm PML risk increases with longer Tysabri treatment duration, particularly beyond two years. In clinical trials, two MS patients developed PML after a median of 120 weeks of treatment, while one Crohn's disease patient developed PML after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The latency period can vary, and symptoms may emerge months after drug discontinuation due to the slow progression of JC virus reactivation. Early diagnosis is challenging because initial symptoms can mimic MS relapses. Delayed recognition may worsen outcomes, underscoring the need for high clinical suspicion in any Tysabri-treated patient presenting with new neurological symptoms.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy that increases the risk of PML, a severe opportunistic brain infection caused by the JC virus. The risk is associated with reduced immune surveillance in the central nervous system due to the drug's mechanism of action. Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Settlement criteria typically involve documented Tysabri exposure and a confirmed PML diagnosis. Key factors include evidence of inadequate warnings, failure to monitor for risk factors (e.g., anti-JCV antibody testing), and the timeline between treatment and symptom onset. Patients should preserve all medical records, including infusion logs and MRI reports, and consult with an attorney experienced in pharmaceutical litigation.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.